Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-label Randomized Controlled Study to Evaluate the Safety and Immunogenicity of nOPV2 at Different Intervals of Administration in Infants

NCT05033561 is registered in ClinicalTrials.gov with Fidec Corporation as lead sponsor.

NCT NCT05033561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05033561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-label Randomized Controlled Study to Evaluate the Safety and Immunogenicity of nOPV2 at Different Intervals of Administration in Infants
Lead sponsor
Fidec Corporation
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2021
Completion date
October 25, 2022
Enrollment
905 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

poliomyelitis